Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Axitinib - Pfizer

Drug Profile

Axitinib - Pfizer

Alternative Names: AG-013736; AG-13,736; Inlyta

Latest Information Update: 06 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Grupo Espanol de Tumores Neuroendocrinos; H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme; Netherlands Cancer Institute; Pfizer; Royal Marsden Hospital; SCRI Development Innovations; SFJ Pharmaceuticals; Sheffield Teaching Hospitals NHS Foundation Trust; University of Cincinnati; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Eye disorder therapies; Imidazoles; Indazoles; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II/III Neuroendocrine tumours
  • Phase II Carcinoid tumour; Colorectal cancer; Glioblastoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Soft tissue sarcoma; Urogenital cancer
  • No development reported Solid tumours
  • Discontinued Breast cancer; Gastric cancer; Gastrointestinal cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 04 Sep 2019 Launched for Renal cell carcinoma (First-line therapy, Combination therapy, Late-stage disease) in Czech Republic, Finland, United Kingdom, Netherlands, Poland, Denmark, Spain, Austria, Belgium, Ireland, Hungary, Greece and Norway (PO)
  • 04 Sep 2019 Registered for Renal cell carcinoma (Late-stage disease, First-line therapy, Combination therapy) in European Union, Iceland, Norway and Liechtenstein (PO)
  • 29 Jul 2019 A decision on prospective marketing authorisation of axitinib in the treatment of Renal cell carcinoma (Late-stage disease, Combination therapy, First-line therapy) by the European Commission is expected in the third quarter of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top